Authors
Latest:
Dr Biachi on the Evolving Role for Surgery in CRCTiago Biachi, MD, PhD, discusses the evolving role for surgery in colorectal cancer.
Latest:
Women in Oncology: Leukemia Therapies in Humans, for HumansJudith Karp, MD, Azra Raza, MD, and Michelle M. Le Beau, PhD, discuss their proudest career accomplishments, including the investigation of potential treatments using a patient’s first cancerous cell, advances in cytogenetics, and a rational design for clinical trials involving cell cytokinetics..
Latest:
Franklin on Strategies to Ameliorate the Effect of Social Determinants on CRC Screening RatesIsabelle Franklin, discusses strategies healthcare providers can implement to address or ameliorate disparities in place that are affecting screening rates in colorectal cancer.
Latest:
Dr Al Malki on Outcomes With PTCy-Based GVHD Prophylaxis in Hematologic MalignanciesMonzr M. Al Malki, MD, discusses outcomes with mismatched unrelated donor transplantation using post-transplant cyclophosphamide–based GVHD prophylaxis.
Latest:
Dr Anders on the Investigation of CCR4 Antagonists in Advanced CancersRobert Albert Anders, MD, PhD, discusses the rationale for developing CCR4 antagonists for use in patients with advanced cancers, including lymphoma and non–small cell lung cancer.
Latest:
Future Management of Chronic Myeloid LeukemiaClosing out their discussion on the management of chronic myeloid leukemia, experts share practical advice and excitement for novel strategies.
Latest:
Dr Berchuck on Detecting PSMA Expression With a Novel Epigenomic Liquid Biopsy in mCRPCJacob E. Berchuck, MD, discusses the use of a novel epigenomic liquid biopsy platform to noninvasively detect PSMA expression in mCRPC.
Latest:
Dr Jimenez on the Radiation Treatment Paradigm in Breast CancerRachel Jimenez, MD, discusses unmet needs in radiation treatment for patients with breast cancer.
Latest:
Dr. Kazmi on Key Treatment Considerations for Young-Onset CRCSyed Kazmi, MD, an oncologist at The University of Texas Southwestern Medical Center, discusses key treatment considerations for young patients with onset colorectal cancer.
Latest:
Unmet Needs and Treatment Trajectory for Patients Diagnosed with Ph+ ALLWith their final thoughts, medical experts share unmet needs in the treatment landscape of Ph+ acute lymphoblastic leukemia.
Latest:
Dr. Casablanca on the Integration of Pembrolizumab in Recurrent or Metastatic Cervical CancerYovanni Casablanca, MD, discusses the integration of pembrolizumab (Keytruda) into the paradigm of recurrent or metastatic cervical cancer.
Latest:
Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond: Guidance and Future PlansIn this final episode of OncChats: Optimizing the Use of Bispecific Antibodies in Myeloma and Beyond, experts discuss plans for developing guidelines and policies to enhance management of bispecific T-cell engagers across various centers.
Latest:
Dr. Iagaru on Advancements in PSMA-PET Imaging for Prostate CancerAndrei H. Iagaru, MD, discusses key points from his presentation on the use of novel vs conventional imaging to manage metastatic hormone-sensitive prostate cancer.
Latest:
Dr. Balzarotti on the Challenges of Treating Elderly DLBCLMonica Balzarotti, MD, discusses the challenges of treating elderly patients with diffuse large B-cell lymphoma.
Latest:
Dr Wolf on Biomarkers Predicting Responses to Immunotherapy in Breast CancerDenise M. Wolf, PhD, discusses research into biomarkers predicting responses to immunotherapy in the phase 2 I-SPY2 trial in patients with early-stage breast cancer.
Latest:
Dr. Kundranda on the Sequencing of Second-Line Therapies in HCCMadappa Kundranda, MD, PhD, discusses the sequencing of second-line therapies in hepatocellular carcinoma.
Latest:
Dr. Michalski on the Goals ASTRO in Radiation OncologyJeff Michalski, MD, MBA, FASTRO, discusses the goals of the American Society for Radiation Oncology in radiation oncology.
Latest:
Immunotherapy Paves Path for New Standards of Care in Gastroesophageal CancersIt is crucial to understand and interpret the results from the landmark clinical trials in the context of recent FDA approvals in gastroesophageal cancers.
Latest:
Dr. Chatzkel on the Rationale for the IMMCO-1 trial in mCRPC and Other Immunologically Cold TumorsJonathan Chatzkel, MD, discusses the rationale for the phase Ib/II IMMCO-1 trial investigating the combination of atezolizumab plus tivozanib in metastatic castration-resistant prostate cancer and other immunologically cold tumors.
Latest:
Dr Borczuk on Currently Offered Gene Testing for Patients With Lung CancerAlain Charles Borczuk, MD, discusses gene testing that may be offered for patients with lung cancer.
Latest:
Best Practices for Virtual Conference PresentationsAs the autumn and winter conference season approaches, Curtis Lachowiez, MD, reflects on the impact 2020 left on the field of oncology.
Latest:
Using Systemic Therapy to Treat HER2+ Breast CancerClosing thoughts from a discussion regarding the treatment landscape for HER2-positive breast cancer, with insight supporting the role of novel therapies to help personalize therapy.
Latest:
Dr Patel on the Evolving Use of Neoadjuvant PD-1 Inhibitors in CSCCVishal Patel, MD, FAAD, FACMS, discusses the evolving use of neoadjuvant and adjuvant PD-1 inhibition in cutaneous squamous cell carcinoma.
Latest:
Expanding Cancer Screening: The Future of Blood-Based TestingClosing out their panel, experts discuss the potential of blood-based tests to democratize access to cancer screening, complement existing protocols, and achieve early detection goals in the fight against cancer.
Latest:
Dr Garrido-Castro on Sacituzumab Govitecan With or Without Pembrolizumab in Metastatic HR+/HER2– Breast CancerAna Christina Garrido-Castro, MD, on sacituzumab govitecan with/without pembrolizumab in metastatic hormone receptor–positive, HER2-negative breast cancer.
Latest:
Dr Appel on the Significance of International Childhood Cancer DayBurton Eliot Appel, MD, discusses the significance of International Childhood Cancer Day.
Latest:
Dr Lin on the Efficacy and Safety of Taletrectinib in ROS1 Fusion+ NSCLCJessica Lin, MD, discusses key findings from the phase 2 TRUST-I trial in patients with ROS1 fusion–positive NSCLC.
Latest:
Clinical Pearls and Closing Thoughts on NSCLC Treatment LandscapeClosing out their discussion on biomarker testing and targeted therapies in non–small cell lung cancer, the panel of expert oncologists share clinical pearls and thoughts on the evolving treatment landscape.
Latest:
Dr Watts on the Final Results of the 2102-HEM-101 Trial in IDH1-Mutated AMLJustin M. Watts, MD, discusses the final 5-year results of the 2102-HEM-101 trial of olutasidenib in patients with IDH1-mutated acute myeloid leukemia.
.jpg?fit=crop&auto=format)
